Jane Street’s Actinium Pharmaceuticals ATNM Stock Holding History

Jane Street’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,700	Closed	-$199K	–	8990
2022 Q4	$199K	Buy	+18,700	New	+$190K	﹤0.01%	7672

Other funds holding ATNM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CFM

Compass Financial Management Tampa, Florida $829M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's ATNM Position: Q2 2026 in Review

Jane Street sold out of Actinium Pharmaceuticals (ATNM) in Q2 2026, closing a stake of 34,299 shares — an estimated $39.6K sold.

Jane Street first reported a position in ATNM in Q2 2015 and held it in 14 quarters. The position peaked at $1.17M in Q1 2023. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

Jane Street reported no remaining Actinium Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jane Street sold 34,299 Actinium Pharmaceuticals shares in Q2 2026, an estimated $39.6K.
Jane Street first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 14 quarters.
Jane Street's Actinium Pharmaceuticals position peaked at $1.17M in Q1 2023.
47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.